Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1<i>H</i>-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT<sub>6</sub>) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
作者:Ramakrishna Nirogi、Anil Shinde、Rama Sastry Kambhampati、Abdul Rasheed Mohammed、Sangram Keshari Saraf、Rajesh kumar Badange、Thrinath Reddy Bandyala、Venugopalarao Bhatta、Kumar Bojja、Veena Reballi、Ramkumar Subramanian、Vijay Benade、Raghava Choudary Palacharla、Gopinadh Bhyrapuneni、Pradeep Jayarajan、Vinod Goyal、Venkat Jasti
DOI:10.1021/acs.jmedchem.6b01662
日期:2017.3.9
04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. It has high selectivity over 5-HT2A receptor. It is orally bioavailable and brain penetrant with robust preclinical efficacy. The combination of 5al, donepezil, and memantine (triple combination) produces synergistic
优化一系列新型的3-(哌嗪基甲基)吲哚衍生物作为5-羟基色胺-6受体(5-HT 6 R)拮抗剂可导致鉴定出1-[((2-溴苯基)磺酰基] -5-甲氧基-3- [ (4-甲基-1-哌嗪基)甲基] -1 H-吲哚二甲酸酯一水合物(5al,SUVN-502)作为潜在治疗认知障碍的临床候选药物。它对人5-HT 6 R具有高亲和力(K i = 2.04 nM),对100个靶位具有选择性,这些靶位包括受体,酶,肽,生长因子,离子通道,类固醇,免疫学因子,第二信使和前列腺素。它具有超过5-HT 2A的高选择性受体。它具有口服生物利用度和脑渗透性,并具有强大的临床前功效。的组合5AL,多奈哌齐,美金刚和(三联组合)产生在腹侧海马乙酰胆碱的细胞外水平的协同效应。三联组合的临床前功效和对5-HT 2A受体的高选择性是区别特征,最终决定了5al的进一步开发。安全性和药代动力学的第一阶段评估已经完成,从而可以启动第二阶段概念验证研究。